Shona Dalal, World Health Organization

World Health Organization

Moderator Of 1 Session

Non-Commercial Satellite
Organizer
World Health Organization (WHO); PATH
Room
Satellite Channel 2
Date
Sat, Jul 4, 2020
Time
06:00 AM - 07:00 AM
Session Description
What's the 2+1+1? In July 2019, the World Health Organization updated its PrEP guidance to include the 4-pill (2+1+1) event-driven (ED)-PrEP dosing regimen for men who have sex with men (MSM). ED-PrEP is as equally efficacious as daily oral PrEP when taken correctly, and provides flexibility and choice to those who may not need a daily pill to protect themselves from HIV. ED-PrEP offers the additional advantage of clear guidance on when to start and stop PrEP, reduced cost to users, and lower drug exposure. This session will highlight first experiences in implementing ED-PrEP in early adopter lower- and middle-income countries, sharing key milestones, lessons learned, and challenges overcome. It will also feature a panel discussion on what can be done to further increase access to ED-PrEP among MSM from the perspectives of policy makers, scientists, advocates, and PrEP users themselves.

Presenter Of 2 Presentations

Oral abstract session

OAC0101 - Introduction

Oral abstract session

OAC0107 - Conclusion

Moderator Of 1 Session

Presenter Of 2 Presentations

Oral abstract session
Oral abstract session

Moderator Of 1 Session

Oral abstract session

Presenter Of 4 Presentations

Non-Commercial Satellite

Simplifying PrEP implementation with the 2+1+1

Oral abstract session
Oral abstract session

Moderator Of 2 Sessions

Oral abstract session
Non-Commercial Satellite
Organizer
World Health Organization (WHO); PATH
Room
Satellite Channel 2
Session Description
What's the 2+1+1? In July 2019, the World Health Organization updated its PrEP guidance to include the 4-pill (2+1+1) event-driven (ED)-PrEP dosing regimen for men who have sex with men (MSM). ED-PrEP is as equally efficacious as daily oral PrEP when taken correctly, and provides flexibility and choice to those who may not need a daily pill to protect themselves from HIV. ED-PrEP offers the additional advantage of clear guidance on when to start and stop PrEP, reduced cost to users, and lower drug exposure. This session will highlight first experiences in implementing ED-PrEP in early adopter lower- and middle-income countries, sharing key milestones, lessons learned, and challenges overcome. It will also feature a panel discussion on what can be done to further increase access to ED-PrEP among MSM from the perspectives of policy makers, scientists, advocates, and PrEP users themselves.